Intellia Therapeutics Inc

30 oct. 2026, 20:03 UTC

Intellia Therapeutics shares fell sharply, continuing a downward trend since Thursday, as negative sentiment lingers from ARKG's decline after a position sell-off.

29 oct. 2026, 23:01 UTC

Intellia Therapeutics, Inc. is trading lower in after-market hours, continuing a downward trend linked to declines in the ARK Genomic Revolution ETF and broader market weakness.

28 oct. 2026, 23:02 UTC

Intellia Therapeutics shares are moving lower in after-market trading, reflecting broader market declines influenced by rising Treasury yields and a widening trade deficit.

27 oct. 2026, 20:02 UTC

Intellia Therapeutics, Inc. shares are sharply higher, reflecting a shift in momentum after a series of higher daily closes since Monday's close.

26 oct. 2026, 23:31 UTC

Intellia Therapeutics Inc shares rose during after-market hours on Monday, recovering from earlier losses but remaining below their 20-day moving average.

23 oct. 2026, 20:07 UTC

Intellia Therapeutics Inc shares are modestly higher, recovering from a significant drop earlier, but remain under pressure and below their 20-day moving average.

22 oct. 2026, 20:07 UTC

Intellia Therapeutics Inc shares are declining amid significant losses in the ARK Genomic Revolution ETF, reflecting ongoing weakness in the biotechnology sector.

21 oct. 2026, 23:06 UTC

Intellia Therapeutics Inc shares advanced in after-market trading, supported by gains in broader equity markets following a decline in U.S. crude oil inventories.

19 oct. 2026, 19:26 UTC

Intellia Therapeutics appoints Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer to support the launch of lonvo-z.

17 oct. 2026, 00:01 UTC

Intellia Therapeutics Inc shares are trading lower in after-market hours, having retraced from earlier gains and reaching a low for the session.

16 oct. 2026, 23:41 UTC

Intellia Therapeutics Inc shares are trading lower in after-market hours, reflecting broader market declines amid concerns over potential Federal Reserve rate hikes.

15 oct. 2026, 22:51 UTC

Intellia Therapeutics Inc saw a notable increase in after-market trading, advancing steadily from a low to a high since Thursday's close.

14 oct. 2026, 23:06 UTC

Intellia Therapeutics Inc shares are trading lower in after-market hours, continuing a decline that began earlier in the session after a brief peak.

13 oct. 2026, 20:07 UTC

Intellia Therapeutics appointed Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026.

12 oct. 2026, 22:52 UTC

Intellia Therapeutics Inc advanced in after-market trading, settling 4.53% above its 20-day moving average and near the upper end of its one-month range.

9 oct. 2026, 20:07 UTC

Intellia Therapeutics Inc shares are advancing amid a broader market rally, regaining momentum after pulling back earlier in the session.

8 oct. 2026, 20:02 UTC

Intellia Therapeutics Inc shares are sharply higher, continuing an upward trend since Wednesday, currently positioned significantly above its 20-day moving average.

7 oct. 2026, 19:56 UTC

Intellia Therapeutics Inc shares fell sharply, reflecting broader biotechnology sector weakness and a decline in the ARK Genomic Revolution ETF amid notable volatility.

6 oct. 2026, 23:05 UTC

Intellia Therapeutics Inc is experiencing a slight increase in after-market trading, positioned near the upper end of its one-month range.

5 oct. 2026, 23:06 UTC

Intellia Therapeutics Inc's shares traded modestly lower during after-market hours, influenced by declines in Beam Therapeutics Inc and Recursion Pharmaceuticals Inc.

3 oct. 2026, 00:01 UTC

Intellia Therapeutics awarded inducement grants for 44.45k shares to new employees, with shares trading modestly lower in after-market hours.

2 oct. 2026, 23:11 UTC

Intellia Therapeutics Inc granted inducement awards of 44.45k restricted stock units to new employees, with the stock trading lower in after-market hours.

1 oct. 2026, 20:07 UTC

Intellia Therapeutics Inc is advancing during Thursday's session, gaining ground since Wednesday's close, despite pulling back from an earlier peak.

30 sept. 2026, 23:20 UTC

Intellia Therapeutics Inc is moving higher in after-market hours, supported by mixed economic indicators, including a revised GDP growth rate of 2.2% for Q2.

29 sept. 2026, 19:15 UTC

Intellia Therapeutics Inc is trading higher, rebounding after four consecutive declines, despite pulling back slightly from an earlier session peak.

28 sept. 2026, 23:11 UTC

Intellia Therapeutics Inc is seeing a modest increase in after-market trading, following a pullback earlier in the session, amid gains in CRISPR Therapeutics AG.

25 sept. 2026, 19:26 UTC

Shares of Prime Medicine Inc fell sharply despite FDA clearance for its gene-editing therapy, continuing a downward trend amid significant volatility.

24 sept. 2026, 19:46 UTC

Intellia Therapeutics Inc shares fell sharply after a weak pre-market start, remaining below the 20-day moving average and near the lower end of its one-month trading range.

23 sept. 2026, 22:11 UTC

Intellia Therapeutics Inc declined sharply in after-market trading, reaching its lowest point of the day and trading well below its 20-day moving average.

21 sept. 2026, 19:16 UTC

Intellia Therapeutics is advancing as it prepares to launch its hereditary angioedema treatment, lonvo-z, following positive Phase III study results.